About Freenome Health
Freenome Health is a company based in United States founded in 2014. Freenome Health has raised $1.35 billion across 8 funding rounds from investors including Fidelity Investments, Verily and Kaiser Permanente. The company has 533 employees as of December 31, 2023. Freenome Health has completed 1 acquisition, including Oncimmune. Freenome Health offers products and services including Intelligent Screening Platform and Early Cancer Detection Tests. Freenome Health operates in a competitive market with competitors including Miroculus, Geneoscopy, UDX, InterVenn and HalioDx, among others.
- Headquarter United States
- Employees 533 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Freenome Holdings, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.35 B (USD)
in 8 rounds
-
Latest Funding Round
$254 M (USD), Series E
Feb 15, 2024
-
Investors
Fidelity Investments
& 54 more
-
Employee Count
533
as on Dec 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Freenome Health
Freenome Health offers a comprehensive portfolio of products and services, including Intelligent Screening Platform and Early Cancer Detection Tests.
Uses AI and multiomics for early cancer detection via blood draws.
Develops and validates tests for treatable cancer stages.
People of Freenome Health
Unlock access to complete
Unlock access to complete
Product Management Team
33 people
Software Development Team
24 people
Leadership Team
18 people
Senior Team
9 people
Human Resources and Administration
5 people
Staff Team
4 people
Data Analysis and Operations Team
4 people
Research Team
2 people
Unlock access to complete
Funding Insights of Freenome Health
Freenome Health has successfully raised a total of $1.35B across 8 strategic funding rounds. The most recent funding activity was a Series E round of $254 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Freenome Health
Freenome Health has secured backing from 55 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Verily and Kaiser Permanente.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BrightEdge is focused on impact investment in cancer care innovation.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in the healthcare sector
|
Locked | Locked | Locked |
Investor details for Freenome Health
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Freenome Health
Freenome Health has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oncimmune.
Investment portfolio details for Freenome Health
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostics and risk assessment solutions for lung cancer are developed.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Freenome Health
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Freenome Health
Detailed financials for Freenome Health
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Freenome Health Comparisons
Peer comparison for Freenome Health
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Freenome Health
Freenome Health operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Miroculus, Geneoscopy, UDX, InterVenn and HalioDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
|
| Locked | Locked | Locked |
Non-invasive blood-based diagnostics for early cancer detection are developed.
|
|
| Locked | Locked | Locked |
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development
|
|
| Locked | Locked | Locked |
Developer of diagnostic product for colon cancer
|
|
| Locked | Locked | Locked |
Digital women's health management software for employers and individuals
|
Detailed competitors of Freenome Health
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Freenome Health
Complete news archive for Freenome Health
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freenome Health
Freenome Health was founded in 2014.
Freenome Health is headquartered in United States.
Freenome Health is a funded company, having raised a total of $1.35B across 8 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Freenome Health is 533.
Freenome Health was founded in 2014 in the United States. A deep learning platform is offered for identifying circulating cancer-related markers in patient blood samples. Proprietary technology is utilized to detect cell-free DNA, immune cell fragments, and metabolic markers. Tumor types are classified through the platform, and treatment therapies for prostate, breast, colorectal, and lung cancers are supported in the health technology sector.
Freenome Health's top competitors include Geneoscopy, UDX and InterVenn.
Freenome Health offers Intelligent Screening Platform and Early Cancer Detection Tests.
Freenome Health has made 1 acquisition, including Oncimmune.
Freenome Health has 55 investors. Key investors include Fidelity Investments, Verily, Kaiser Permanente, Intermountain Healthcare, and Roche.